Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
30 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
GlycoVaxyn AG - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'GlycoVaxyn AG - Product Pipeline Review - 2014', provides an overview of the GlycoVaxyn AG's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of GlycoVaxyn AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of GlycoVaxyn AG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of GlycoVaxyn AG's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the GlycoVaxyn AG's pipeline products Reasons to buy - Evaluate GlycoVaxyn AG's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of GlycoVaxyn AG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the GlycoVaxyn AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of GlycoVaxyn AG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of GlycoVaxyn AG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of GlycoVaxyn AG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 GlycoVaxyn AG Snapshot 5 GlycoVaxyn AG Overview 5 Key Information 5 Key Facts 5 GlycoVaxyn AG - Research and Development Overview 6 Key Therapeutic Areas 6 GlycoVaxyn AG - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 GlycoVaxyn AG - Pipeline Products Glance 11 GlycoVaxyn AG - Clinical Stage Pipeline Products 11 Phase I Products/Combination Treatment Modalities 11 GlycoVaxyn AG - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Discovery Products/Combination Treatment Modalities 13 GlycoVaxyn AG - Drug Profiles 14 extraintestinal pathogenic escherichia coli vaccine 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 GVXNSD-133 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 meningococcal meningitis vaccine 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Staphylococcus aureus vaccine 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 streptococcus pneumoniae vaccine 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 uropathogenic escherichia coli vaccine 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 bacterial conjugate vaccine 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 enterotoxigenic escherichia coli conjugate Vaccine 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 multivalent bacterial vaccine 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 pseudomonas aeruginosa conjugate vaccine 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 streptococcus vaccine 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 GlycoVaxyn AG - Pipeline Analysis 25 GlycoVaxyn AG - Pipeline Products by Route of Administration 25 GlycoVaxyn AG - Pipeline Products by Molecule Type 26 GlycoVaxyn AG - Recent Pipeline Updates 27 GlycoVaxyn AG - Locations And Subsidiaries 28 Head Office 28 Appendix 29 Methodology 29 Coverage 29 Secondary Research 29 Primary Research 29 Expert Panel Validation 29 Contact Us 30 Disclaimer 30
List of Tables GlycoVaxyn AG, Key Information 5 GlycoVaxyn AG, Key Facts 5 GlycoVaxyn AG - Pipeline by Indication, 2014 8 GlycoVaxyn AG - Pipeline by Stage of Development, 2014 9 GlycoVaxyn AG - Monotherapy Products in Pipeline, 2014 10 GlycoVaxyn AG - Phase I, 2014 11 GlycoVaxyn AG - Preclinical, 2014 12 GlycoVaxyn AG - Discovery, 2014 13 GlycoVaxyn AG - Pipeline by Route of Administration, 2014 25 GlycoVaxyn AG - Pipeline by Molecule Type, 2014 26 GlycoVaxyn AG - Recent Pipeline Updates, 2014 27
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.